BIOMAT Database Logo BIOMAT Database Logo

Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome. 2004

Nicola Gianotti, and Alessandro Soria, and Laura Galli, and Barbara Giudici, and Giuliana Fusetti, and Adriano Lazzarin, and Enzo Boeri, and Antonella Castagna

UI MeSH Term Description Entries
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016014 Linear Models Statistical models in which the value of a parameter for a given value of a factor is assumed to be equal to a + bx, where a and b are constants. The models predict a linear regression. Linear Regression,Log-Linear Models,Models, Linear,Linear Model,Linear Regressions,Log Linear Models,Log-Linear Model,Model, Linear,Model, Log-Linear,Models, Log-Linear,Regression, Linear,Regressions, Linear
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts
D023241 Antiretroviral Therapy, Highly Active Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor. Combination Antiretroviral Therapy,HAART,Highly Active Antiretroviral Therapy,Antiretroviral Therapies, Combination,Antiretroviral Therapy, Combination,Combination Antiretroviral Therapies,Therapies, Combination Antiretroviral,Therapy, Combination Antiretroviral
D024921 Drug Resistance, Multiple, Viral The ability of viruses to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance phenotype may be attributed to multiple gene mutation. Drug Resistance, Extensive, Viral,Drug Resistance, Extensively, Viral,Extensive Antiviral Drug Resistance,Extensively Antiviral Drug Resistance,Multidrug Resistance, Viral,Multiple Antiviral Drug Resistance,Resistance, Viral Multidrug,Viral Multidrug Resistance,Viral Multidrug Resistances

Related Publications

Nicola Gianotti, and Alessandro Soria, and Laura Galli, and Barbara Giudici, and Giuliana Fusetti, and Adriano Lazzarin, and Enzo Boeri, and Antonella Castagna
Single-Boosted Protease Inhibitor versus Double-Boosted Protease Inhibitors for the Salvage Therapy in HIV-Infected Patients.
January 2011, Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002),
Nicola Gianotti, and Alessandro Soria, and Laura Galli, and Barbara Giudici, and Giuliana Fusetti, and Adriano Lazzarin, and Enzo Boeri, and Antonella Castagna
Protease inhibitor-sparing regimen suppresses HIV.
December 1998, AIDS patient care and STDs,
Nicola Gianotti, and Alessandro Soria, and Laura Galli, and Barbara Giudici, and Giuliana Fusetti, and Adriano Lazzarin, and Enzo Boeri, and Antonella Castagna
A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.
January 2012, Antiviral therapy,
Nicola Gianotti, and Alessandro Soria, and Laura Galli, and Barbara Giudici, and Giuliana Fusetti, and Adriano Lazzarin, and Enzo Boeri, and Antonella Castagna
Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.
October 2012, The Journal of antimicrobial chemotherapy,
Nicola Gianotti, and Alessandro Soria, and Laura Galli, and Barbara Giudici, and Giuliana Fusetti, and Adriano Lazzarin, and Enzo Boeri, and Antonella Castagna
Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children.
September 2006, AIDS (London, England),
Nicola Gianotti, and Alessandro Soria, and Laura Galli, and Barbara Giudici, and Giuliana Fusetti, and Adriano Lazzarin, and Enzo Boeri, and Antonella Castagna
Characterization of HIV-1 from patients with virological failure to a boosted protease inhibitor regimen.
March 2011, Journal of medical virology,
Nicola Gianotti, and Alessandro Soria, and Laura Galli, and Barbara Giudici, and Giuliana Fusetti, and Adriano Lazzarin, and Enzo Boeri, and Antonella Castagna
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
November 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Nicola Gianotti, and Alessandro Soria, and Laura Galli, and Barbara Giudici, and Giuliana Fusetti, and Adriano Lazzarin, and Enzo Boeri, and Antonella Castagna
Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study.
February 2013, The Journal of antimicrobial chemotherapy,
Nicola Gianotti, and Alessandro Soria, and Laura Galli, and Barbara Giudici, and Giuliana Fusetti, and Adriano Lazzarin, and Enzo Boeri, and Antonella Castagna
Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.
May 2008, The Journal of antimicrobial chemotherapy,
Nicola Gianotti, and Alessandro Soria, and Laura Galli, and Barbara Giudici, and Giuliana Fusetti, and Adriano Lazzarin, and Enzo Boeri, and Antonella Castagna
Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir).
April 2010, Journal of clinical pharmacology,
Copied contents to your clipboard!